-
Top 100 new drug registration applications of national pharmaceutical enterprises in 2013
Time of Update: 2020-04-03
Note: 1 The ranking order is based on the total number of clinical application and production approval acceptance numbers in 2013; 2 Because the ranking is based on the total number of acceptance numb
-
Application for registration of new lung cancer drug toluenesulfonamide production of HongRi Pharmaceutical Co., Ltd. accepted
Time of Update: 2020-04-03
In the afternoon of May 19, HongRi pharmaceutical announced that the application for production registration of p-toluenesulfonamide (hereinafter referred to as "PTS") jointly declared by the company
-
Xiamen Tebao a new drug pegylated interferon α - 2b injection officially declared for production
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA), Tonghua Dongbao joint stock company Xiamen Tebao Bioengineering Co., Ltd has officially applied for the production of polyeth
-
Haizheng Pharmaceutical Co., Ltd. applied for clinical application of class 3.1 chemical drug API for sirolimus and was accepted
Time of Update: 2020-04-03
Recently, according to the website of the State Food and Drug Administration (CFDA), the 3.1 chemical raw material drug tirocimose and preparation injection tirocimose applied for clinical application
-
A new anti hepatitis drug of Guizhou bailing, tefentai, will be put into clinical trial soon
Time of Update: 2020-04-03
Recently, the latest status of Guizhou bailing's heavyweight drug, tefentai (original Y101), was changed to "approved - to be certified" This means that the company's class 1.1 innovative drug, tefent
-
Approved clinical approval of kazinan 1.1 new drug CM082
Time of Update: 2020-04-03
The processing status of CM082 (cxhl1301192), a class 1.1 new drug of kananji Pharmaceutical Technology (Shanghai), was changed to "CFDA approval" on December 19, 2014, and clinical approval documents
-
Zuelacetan, an antiepileptic drug of Jingxin pharmaceutical, has obtained new drug certificate and registration approval
Time of Update: 2020-04-03
Zhejiang Jingxin pharmaceutical announced that the company and its wholly-owned subsidiary Shangyu Jingxin Pharmaceutical Co., Ltd received the new drug certificate (Certificate No.: gdzzh20140034) ap
-
Haizheng pharmaceutical's class 3.1 new drug gefitinib API has been accepted
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA), the class 3.1 new drug gefitinib API declared by Haizheng pharmaceutical was accepted At present, only the original research
-
The project of taxol derivative, a class I and type II new antidiabetic drug of Haixi United Pharmaceutical Co., Ltd. was officially launched in Mingxi
Time of Update: 2020-04-03
Fujian Haixi United Pharmaceutical Co., Ltd and China University of Pharmaceutical Sciences jointly implemented a class I new drug taxol derivative (type II new anti diabetes drug) project, which was
-
Shuangcheng pharmaceutical focuses on clinical re declaration after withdrawal of etibatide for injection
Time of Update: 2020-04-03
Hainan Shuangcheng Pharmaceutical Co., Ltd focuses on the research of etibatide, which has attracted market attention since the withdrawal of registration application last year The company said in a p
-
Three specifications of irbesartan hydrochlorothiazide tablets of Huahai Pharmaceutical Co., Ltd. have been approved by FDA for listing
Time of Update: 2020-04-03
In the evening of May 12, Huahai pharmaceutical announced that the company's three specifications of irbesartan hydrochlorothiazide tablets were approved by FDA for listing Irbesartan hydrochlorothiaz
-
The first artificial drug of humanwell is expected to go on sale in the second half of the year
Time of Update: 2020-04-03
Li Jie, chairman of Yichang humanwell, a subsidiary of humanwell pharmaceutical, said at the institutional research meeting on March 26 that the company's newly approved narcotic and analgesic drug, n
-
Roche's Chugai non-small cell lung cancer targeting drug alectinib approved by Japan
Time of Update: 2020-04-03
Alectinib, the latest targeted drug for anaplastic lymphoma kinase (ALK) - positive non-small cell lung cancer, has been approved for the first time in Japan The anti-tumor drug will be introduced to
-
The University of Hong Kong has successfully developed a new influenza A vaccine
Time of Update: 2020-04-03
Recently, the University of Hong Kong has successfully developed a new influenza A vaccine The inoculated mice can prevent the infection of a variety of a influenza viruses including h7n9 A avian infl
-
Changshan pharmaceutical sodium hyaluronate has completed clinical trials
Time of Update: 2020-04-03
Zhang Wei, financial director and Secretary of Changshan pharmaceutical industry, said in a conference call that at present, the main construction of the company's sodium hyaluronate new car room has
-
Application for production of bortezomib for injection of six chemical drugs in Haizheng Pharmaceutical Co., Ltd. was accepted
Time of Update: 2020-04-03
Bortezomib for injection, a 6-class chemical drug declared by Haizheng pharmaceutical, has been accepted According to the inquiry, the company has previously applied for bortezomib as the drug substan
-
Adenosylmethionine succinate, a new hepatobiliary drug from Zhenyuan, Zhejiang Province, is expected to obtain production approval in the first half of the year
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on March 20, the three in one review of adenosylmethionine succinate bulk drug and injection, a new hepatobiliary drug declare
-
Three new indications of pegylated recombinant human growth hormone injection in Jinsai pharmaceutical were approved
Time of Update: 2020-04-03
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete without any false record, misleading statement or major omission T
-
Shenzhen Institute of advanced technology, Chinese Academy of Sciences: ultrasound administration or reversal of multidrug resistance
Time of Update: 2020-04-03
On December 17, the reporter learned from Shenzhen Institute of advanced technology of Chinese Academy of Sciences that Zheng Hailong's research group of the Institute of medical engineering of Chines
-
Qianhong pharmaceutical's development of new drugs has been frustrated and antithrombotic protein has been withdrawn from trial
Time of Update: 2020-04-03
Today (November 7), the investors of Qianhong pharmaceutical finally waited for the latest news of the company's heavyweight new drug, recombinant human antithrombotic protein for injection (hereinaft
